MaryAnn Go

Statistics

Publications

Citations

609

H-Index

Active since

2012

Affiliations

Gene Therapy Laboratory(Current)

University of York

Hull York Medical School

MaryAnn Go is an author at Gene Therapy Laboratory specializing in antibody conjugates, antibody-drug conjugates, and antibody-drug conjugate therapy.

Publications per year

2012–2024

Publications

A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Shang‐Fan Yu, Bing Zheng, MaryAnn Go et al. · Clinical Cancer Research · 2015 · 162 citations

Medicine, Oncology, Pharmacology +17

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates

Leanna R. Staben, Stefan G. Koenig, Sophie M. Lehar et al. · Nature Chemistry · 2016 · 153 citations

Pharmacy, Medicinal Chemistry, Pharmaceutics +17

FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

Kristi Elkins, Bing Zheng, MaryAnn Go et al. · Molecular Cancer Therapeutics · 2012 · 88 citations

Pharmacy, Immunology, Pharmacology +17

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Dongwei Li, Kirsten Achilles Poon, Shang‐Fan Yu et al. · Molecular Cancer Therapeutics · 2013 · 85 citations

Pharmacy, Oncology, Pharmacokinetics +17

ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1

Simon‐Peter Williams, Annie Ogasawara, Jeff N. Tinianow et al. · Oncotarget · 2016 · 34 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +16

1–5 of 9